O'Neal Comprehensive Cancer Center Magazine Spring 2020 | Page 9

APARNA HEGDE, M.D., is an assistant professor of Medicine in the Division of Hematology &
Oncology and associate scientist in the O’Neal Comprehensive Cancer Center. She comes to UAB
from the MD Anderson Cancer Center. Hegde’s clinical practice focuses on the care of lung patients,
while her research interests are in lung cancer screening, drug development in non-metastatic lung
cancer and immune-related adverse events.
OMER JAMY, M.D., is an assistant professor of Medicine in the Division of Hematology & Oncology
and associate scientist in the O’Neal Comprehensive Cancer Center. Jamy’s clinical work is in the care
of patients with hematological malignancies, including patients receiving bone marrow transplants
and cellular therapy. His research focuses on understanding the factors that influence the outcomes
of patients with myeloid neoplasms, particularly acute myeloid leukemia, and the development of
strategies to improve therapeutic decision making.
MYTHREYE KARTHIKEYAN, PH.D., M.SC., is an associate professor of Pathology in the Division
of Molecular & Cellular Pathology and a scientist in the O’Neal Comprehensive Cancer Center.
Karthikeyan’s research program spans the field of intrercellular and intracellular signal transduction
and tumor progression and metastasis. Her goal is to improve therapeutic outcomes by developing
an in-depth understanding of the molecular mechanisms of metastasis due to altered growth factor
availability and signaling, particularly in gynecological cancers.
MAYUR NARKHEDE, M.D., is an assistant professor of Medicine in the Division of Hematology &
Oncology and associate scientist in the O’Neal Comprehensive Cancer Center. He comes to UAB from
the Georgetown Lombardi Comprehensive Cancer Center. Narkhede’s clinical interests are in the
care of patients with lymphomas and chronic lymphocytic leukemia. His research focuses on indolent
lymphomas, translating novel observations into clinical trials and identifying biomarkers of resistance
and response.
MARY KATHRYN SEWELL-LOFTIN, PH.D., is an assistant professor of Biomedical Engineering and
associate scientist in the O’Neal Comprehensive Cancer Center. She comes to UAB from Washington
University in St. Louis. Her research interests include developing novel models to study how
biomechanical forces impact cancer growth in order to develop anti-tumor treatment strategies.
She also has expertise in tissue engineering, specifically when related to studying the interaction of
biomaterials, mechanics and cell behaviors.
ERIC UBIL, MBA, PH.D., is an assistant professor of Microbiology and associate scientist in the O’Neal
Comprehensive Cancer Center. He comes to UAB from the University of North Carolina at Chapel
Hill. Ubil is using pharmacological inhibitors of Pros1: Mer signaling to prevent tumor-derived immune
suppression in pre-clinical models.
ERWIN G. VAN MEIR, PH.D., is a professor of Neurosurgery and senior scientist in the O’Neal
Comprehensive Cancer Center. He comes to UAB from the Winship Cancer Institute at Emory
University. Van Meir’s laboratory research focuses on understanding the molecular basis for human
tumor development, such as genetic alterations and hypoxia, and how this knowledge can be used to
devise new therapeutics that will improve patient survival.
UAB.EDU/CANCER
7